FDA Issues Warning on Severe Lung Inflammation With CDK4/6 Inhibitors in Breast Cancer

Sep 13, 2019 – The FDA is updating the prescribing information and Patient Package Insert for the CDK4/6 inhibitors palbociclib, ribociclib, and abemaciclib to include a warning that the treatments in rare cases may cause severe inflammation of the lungs. The inflammation can be life-threatening, so the FDA recommends that patients receiving CDK4/6 inhibitors should immediately contact their healthcare professional if they experience shortness of breath with … (leggi tutto)